Roles of Neutrophil/lymphocyte Ratio in Prognosis and in Differentiation of Potential Beneficiaries in HER2-positive Breast Cancer with Trastuzumab Therapy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 Mar 21

PMID 32192443

Citations 9

Authors

Nianhua Ding

Juan Huang

Ningsha Li

Jiaqi Yuan

Shouman Wang

Zhi Xiao

Affiliations

Soon will be listed here.

Abstract

Background: The relationship of neutrophil/lymphocyte ratio (NLR) to prognosis of HER2-positive breast cancer (BC) is not well studied. We aimed to assess the prognostic role of NLR in HER2-positive BC patients treated with or without trastuzumab.

Methods: The clinical data of 843 HER2-positive BC patients from July 2013 to July 2018 were collected. The difference among variables was calculated by chi-square test. The associations between clinicopathological factors, NLR and disease-free survival (DFS) were analyzed by univariate and multivariate analyses.

Results: Patients were divided into three groups. In group 1 containing 255 patients without trastuzumab treatment, pretreatment NLR showed no predictive value. Patients with trastuzumab treatment were divided into two groups on equal, according to pretreatment NLR values, low NLR (group 2) and high NLR (group 3). Patients in group 2 showed significantly higher 3-year DFS rate than patients in group 1 and group 3 (95.3% vs. 91.6% vs. 90.5%, respectively, P = 0.011); patients in the group 1 and group 3 had a similar 3-year DFS outcome. Multivariate analysis showed high pretreatment NLR was significantly associated with shorter DFS (HR = 2.917, 95% CI = 1.055-8.062, P = 0.039) in HER2-positive BC patients treated with trastuzumab.

Conclusions: Among HER2-positive trastuzumab-treated BC patients, low pretreatment NLR value was associated with better DFS, and it might help to differentiate potential beneficiaries of trastuzumab treatment.

Citing Articles

Association of inflammatory blood markers and pathological complete response in HER2-positive breast cancer: a retrospective single-center cohort study.

Chen X, Cai Q, Deng L, Chen M, Xu M, Chen L Front Immunol. 2024; 15:1465862.

PMID: 39628488 PMC: 11611895. DOI: 10.3389/fimmu.2024.1465862.

Prognostic Value of the Baseline Systemic Immune-Inflammation Index in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Two Prospective Trials.

Pang J, Ding N, Liu X, He X, Zhou W, Xie H Ann Surg Oncol. 2024; 32(2):750-759.

PMID: 39565489 DOI: 10.1245/s10434-024-16454-8.

Systemic immune-inflammation index as a prognostic marker in HER2-positive breast cancer patients undergoing trastuzumab therapy.

Pang J, Ding N, Yin N, Xiao Z Sci Rep. 2024; 14(1):6578.

PMID: 38503890 PMC: 10951263. DOI: 10.1038/s41598-024-57343-0.

Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial.

Ding N, Pang J, Liu X, He X, Zhou W, Xie H Breast Cancer Res. 2024; 26(1):9.

PMID: 38212845 PMC: 10785455. DOI: 10.1186/s13058-023-01761-x.

Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study.

Hao L, Dong J, Yu H, Chen J, Han X, Pan Y Transl Cancer Res. 2023; 12(10):2726-2741.

PMID: 37969380 PMC: 10643952. DOI: 10.21037/tcr-23-1078.

References

Araki K, Ito Y, Fukada I, Kobayashi K, Miyagawa Y, Imamura M . Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel. BMC Cancer. 2018; 18(1):982. PMC: 6191898. DOI: 10.1186/s12885-018-4888-2. View

Collins D, ODonovan N, McGowan P, OSullivan F, Duffy M, Crown J . Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 2011; 23(7):1788-95. DOI: 10.1093/annonc/mdr484. View

Bronte V, Zanovello P . Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005; 5(8):641-54. DOI: 10.1038/nri1668. View

Ding N, Huang T, Yuan J, Mao J, Duan Y, Liao W . Yes-associated protein expression in paired primary and local recurrent breast cancer and its clinical significance. Curr Probl Cancer. 2019; 43(5):429-437. DOI: 10.1016/j.currproblcancer.2018.12.005. View

Schmielau J, Finn O . Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001; 61(12):4756-60. View

Wang D, Bai N, Hu X, OuYang X, Yao L, Tao Y . Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ. 2019; 7:e7132. PMC: 6796955. DOI: 10.7717/peerj.7132. View

Hong J, Chen X, Gao W, Zhu S, Wu J, Huang O . A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab. Cancer Manag Res. 2019; 11:3371-3379. PMC: 6497860. DOI: 10.2147/CMAR.S187233. View

Yersal O, Cetinkunar S, Aktimur R, Aziret M, Ozdas S, Erdem H . Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios are Not Different among Breast Cancer Subtypes. Asian Pac J Cancer Prev. 2017; 18(8):2227-2231. PMC: 5697485. DOI: 10.22034/APJCP.2017.18.8.2227. View

Gianni L, Dafni U, Gelber R, Azambuja E, Muehlbauer S, Goldhirsch A . Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011; 12(3):236-44. DOI: 10.1016/S1470-2045(11)70033-X. View

10.

Mouchemore K, Anderson R, Hamilton J . Neutrophils, G-CSF and their contribution to breast cancer metastasis. FEBS J. 2017; 285(4):665-679. DOI: 10.1111/febs.14206. View

11.

Afghahi A, Purington N, Han S, Desai M, Pierson E, Mathur M . Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res. 2018; 24(12):2851-2858. PMC: 6366842. DOI: 10.1158/1078-0432.CCR-17-1323. View

12.

Yu L, Tang J, Zhang C, Zeng W, Yan H, Li M . New Immunotherapy Strategies in Breast Cancer. Int J Environ Res Public Health. 2017; 14(1). PMC: 5295319. DOI: 10.3390/ijerph14010068. View

13.

Baselga J . Treatment of HER2-overexpressing breast cancer. Ann Oncol. 2010; 21 Suppl 7:vii36-40. DOI: 10.1093/annonc/mdq421. View

14.

Swierczak A, Mouchemore K, Hamilton J, Anderson R . Neutrophils: important contributors to tumor progression and metastasis. Cancer Metastasis Rev. 2015; 34(4):735-51. DOI: 10.1007/s10555-015-9594-9. View

15.

Jia H, Truica C, Wang B, Wang Y, Ren X, Harvey H . Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Drug Resist Updat. 2017; 32:1-15. DOI: 10.1016/j.drup.2017.07.002. View

16.

Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G . Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007; 67(24):11991-9. DOI: 10.1158/0008-5472.CAN-07-2068. View

17.

Miyagawa Y, Araki K, Bun A, Ozawa H, Fujimoto Y, Higuchi T . Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel. Clin Breast Cancer. 2018; 18(5):400-409. DOI: 10.1016/j.clbc.2018.03.002. View

18.

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K . Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2017; 19(1):40-50. DOI: 10.1016/S1470-2045(17)30904-X. View

19.

Arteaga C, Sliwkowski M, Osborne C, Perez E, Puglisi F, Gianni L . Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011; 9(1):16-32. DOI: 10.1038/nrclinonc.2011.177. View

20.

Rimawi M, Schiff R, Osborne C . Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28. DOI: 10.1146/annurev-med-042513-015127. View